107813-50-3Relevant academic research and scientific papers
HETEROARYL COMPOUNDS AS PDE10A INHIBITORS
-
Page/Page column 35, (2011/11/06)
The present invention provides heteroaryl compounds as Phosphodiesterase 10A (PDE I OA) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phosphodiesterase 10A enzyme. Also provided herein are processes for preparing compounds described herein, Formula (I), intermediates used in their synthesis, pharmaceutical compositions thereof.
Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same
-
Page/Page column 59, (2008/06/13)
Amidine compounds of the formula wherein the substituents are defined as in the application useful as NO-synthase enzyme inhibitors.
Quinolinoxy phenylsulphonamides
-
, (2008/06/13)
New phenylsulphonamide of the formula in which STR1 R1 represents a pyridyl, quinolyl or isoquinolyl radical which is unsubstituted or substituted by halogen, alkyl, cycloalkyl, alkoxy, cyano, nitro, halogenoalkyl, halogenoalkoxy, alkoxycarbonyl or alkylsulphonyl, R2 represents hydrogen, cyano, nitro, halogen, alkyl, alkoxy, halogenoalkyl, halogenoalkoxy or alkoxycarbonyl, R3 represents an aryl radical which is unsubstituted or monosubstituted, disubstituted or trisubstituted by halogen, halogenoalkyl, halogenoalkoxy, alkyl, alkoxy, alkylthio, alkylsulphonyl, cyano, nitro or alkoxycarbonyl, the substituents being identical or different, or represents pentafluorophenyl or represents a straight-chain, branched or cyclic alkyl which is unsubstituted or substituted by halogen, aryl, aryloxy, cyano, alkoxycarbonyl, alkoxy, alkylthio or trifluoromethyl, and X represents an --O--, --A--B-- or --B--A-- group where A denotes --O--, STR2 and B denotes --CH2 -- or STR3 where R1 does not represent a pyridyl radical when x represents an --O-- group, and salts thereof are prepared by reacting appropriate amines with sulphonyl halides. The substituted phenylsulphonamides can be employed as active compounds for inhibiting enzymatic reactions and for inhibiting thrombocyte aggregations.
N- and N- Sulfonamides: Potent Orally Active Leukotriene D4 Antagonists of Novel Structurs
Musser, John H.,Kreft, Anthony F.,Bender, Reinhold H. W.,Kubrak, Dennis M.,Carlson, Richard P.,et al.
, p. 1176 - 1183 (2007/10/02)
Two series of compounds, N- sulfonamides and N- sulfonamides, were prepared as leukotriene D4 (LTD4) antagonists.In the phenyl series, N--trifluoromethanesulfonamide (Wy-48,252, 16) was the most potent inhibitor of LTD4-induced bronchoconstriction in the guinea pig.With an intragastric ID 50 of 0.1 mg/kg (2-h pretreatment), 16 was 300 times more potent than LY-171,883.Compound 16 also intragastrically inhibited ovalbumin-induced bronchoconstriction in the guinea pig with an ID 50 of 0.6mg/kg.In vitro against LTD4-induced contraction of isolated guinea pig trachea pretreated with indomethacin and L-cysteine, 16 produced a pKB value of 7.7.In the rat PMN assay 16 inhibited both 5-lipoxygenase and cyclooxygenase (IC 50's = 4.6 and 3.3 μM).In the naphthyl series, N-trifluoromethanesulfonamide (Wy-48,090, 47) in addition to potent LTD4 antagonist activity (on isolated guinea pig trachea 47 had a pKB value of 7.04) also had antiinflammatory activity (63percent inhibition at 50 mg/kg in the rat carrageenan paw edema assay and 34percent inhibition of TPA-induced inflammation at 1 mg/ear in the mouse ear edema model).Perhaps the antiinflammatory activity of 47 was due to its additional activity of inhibiting both 5-lipoxygenase and cyclooxygenase enzymes (IC 50's = 0.23 and 11.9 μM, respectively, in rat PMN).
Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
-
, (2008/06/13)
The present invention is concerned with the therapeutic composition comprising as an active ingredient a compound of the formula: and salts thereof; wherein Ar and Ar1 are independently phenyl, naphthyl or a nitrogen, oxygen, or sul
